04/21/2026
A new paper in the Journal of Clinical Investigation Insight for the NEI funded collaborative Glaucoma project of the Gronert and Flanagan Labs at Berkeley and Sivak Lab at the University of Toronto.
Prostaglandin analogues, such as latanoprost, are the first-line treatment to reduce ocular hypertension in the management of glaucoma. The mechanism of actions for latanoprost are not well defined.
The team discovered that in glaucoma patients a protective and anti-inflammatory lipid signal, lipoxin A4, was unexpectedly elevated in the aqueous humor.
Read More:
https://vision.berkeley.edu/posts/paper-from-gronert-flanagan-labs/